Introduction
Dendritic cell (DC) biology has greatly evolved since DCs were first identified and described by Steinman et al. in 1973 1 . It is now well accepted that DCs derived from bone marrow hematopoietic stem cells are not only potent immune inducers, linking innate and adaptive immunity but they are also essential for the induction and maintenance of tolerance 2 . DCs are important modulators of T cell phenotype and function, providing the signals required for T cells to become fully activated effector or regulatory cells 3 . All of these DC functions are dependent on the phenotypical state and the immunological environment within which the DCs find themselves 2 . In recent years manipulation of DC maturation, by altering the expression level of MHCII and costimulatory molecules, has been investigated by treating DCs with various cytokines or pharmaceutical agents [4] [5] [6] [7] [8] , resulting in the generation of immature or regulatory DC phenotypes. This has generated considerable interest within the field of transplantation immunology as presently immunosuppressive drug therapy is the main rejection prophylaxis, with which harmful toxic side effects are associated. Accordingly, modified DC therapies for the promotion of allograft survival are an attractive and promising alternative. Administration of immature regulatory DCs has been investigated with varying degrees of efficacy in multiple transplantation models and it has become evident that the role of DCs in the immune response and allograft rejection is complex and dependant on a variety of factors including the source (recipient or donor) of the DCs, the nature of the DCs, the level of maturation, the environment in which the DCs become activated and the model within which the DCs are administered [9] [10] [11] [12] . Recently in models of islet and skin transplantation it has been demonstrated that pre-treatment of donor derived tolerogenic DCs may be linked to an increased risk of sensitisation of the recipient immune system rather than tolerance induction 9, 13 . Although autologous tolerogenic DCs are being investigated 14, 15 and preclinical studies with an aim to develop tolerogenic monocyte-derived DC for a clinical application have begun 16 a comprehensive analysis of the mechanisms involved and characterisation of both autologous and donor derived DC mediated tolerance induction is required.
DC application in corneal transplantation remains relatively uninvestigated and only recently it was demonstrated that regulatory donor DCs suppress the indirect pathway of allosensitization in corneal transplantation, an important observation for the development of cell therapies for corneal transplantation as the cornea is the most commonly transplanted tissue 8, 17 . The eye is described as an immune privileged organ, though this privilege is in a dynamic rather than a static state as not all corneal allografts succeed in humans or in experimental animals 18 . Although corneal transplantation is a relatively risk free uncomplicated procedure with 90% survival within the first year post transplantation, the five year prognosis is similar to that of renal, liver or cardiac allografts with rejection remaining as the main cause of allograft failure 19 . The application of ex-vivo generated Dexa treated BMDCs has not been demonstrated, to our knowledge, in corneal transplantation.
We hypothesised that administration of donor derived Dexa BMDCs will promote corneal allograft survival. To test this hypothesis in the present study we have fully characterised the phenotype and immunomodulatory properties of Dexa BMDCs in both quiescent and inflammatory conditions with untreated BMDCs serving as a control. We also investigated the administration of both donor untreated BMDCs and Dexa treated BMDCs to promote corneal allograft survival, obviating the need for immunosuppression. We aimed to describe and characterise in detail the local immune environment at the level of both the graft and the draining lymph nodes (LNs) as a result of these cell therapies. 
Results
Phenotypical and functional characterisation of ex-vivo generated BMDCs and Dexa
BMDCs.
Bone marrow cells were differentiated in the presence of rat GM-CSF and IL-4 (5ng/ml respectively). For dexamethasone (Dexa) treated cultures a final concentration of 10 -6 M of the glucocorticoid was added to the culture every other day from day 4. The phenotype of BMDCs was analysed by flow cytometry on day 10. Gating on the CD11b/c+ population, the percentage expression levels of MHCII and the co-stimulatory molecules CD80 and CD86 indicated a semi-mature BMDC phenotype (Fig. 1a) . Treatment of BMDCs with Dexa resulted in a significant reduction in the expression level of these maturation markers (Fig. 1a) . To investigate expression of co-stimulatory molecules under inflammatory conditions, semimature BMDC cultures were stimulated for 24hrs with LPS (1µg/ml) and analysed for expression of MHCII, CD80 and CD86. Results illustrated that LPS stimulated Dexa BMDCs had a significantly lower level of expression of these maturation molecules compared to LPS stimulated BMDC cultures. Expression of these maturation markers did not change significantly from unstimulated Dexa BMDCs, indicating that this DC population was maturation resistant (Fig.1a) . Supernatants from day 10 cultures of unstimulated and LPS stimulated (24hrs) BMDC and Dexa BMDC cultures were analysed for the presence of the cytokines TNF-α and IL-10 ( Fig. 1b) . LPS stimulated Dexa BMDCs produced significantly higher amounts of IL-10 and lower amounts of TNF-α compared to BMDCs (Fig. 1b) . (Fig. 2a) . While both BMDC treatments resulted in a significant reduction of corneal opacity, corneal neovascularization was not affected by either BMDC injection (Fig. 2b) .
Clinical evaluation of the corneal allografts by light and slit lamp microscopy followed by histological analysis confirmed a significant reduction in the level of infiltration of inflammatory cells on day 18 (average day of rejection) and on day 30 after transplantation for both treated groups (Fig. 2c,d ). Evidence of reduced corneal thickness was observed at day 30 for both treatments ( Investigation into the mechanism of untreated BMDC and Dexa BMDC mediated prolongation of corneal allograft survival.
To further characterise untreated BMDC and Dexa BMDCs mechanism to promote survival of corneal allografts, we examined the phenotype of the cell populations infiltrating the allograft and in secondary lymphoid organs by flow cytometry and RT-PCR. As expected, the significantly reduced corneal opacity levels correlated with a significant reduction in the absolute number of cells isolated from corneal allografts for both treatments ( Evaluation of peripheral donor specific unresponsiveness and alloantibody production after donor untreated BMDC and Dexa BMDC administration.
To examine the induction of peripheral donor specific unresponsiveness following BMDC and Dexa BMDCs treatment a strategy was devised where grafted animals day 65 -80 post transplantation were rechallenged with donor antigen (Fig. 4a) . Injection of complete mismatched cells to donor and recipient (3 rd party Sprague Dawley (CD) rats) which mimics first time exposure to an antigen were used as a control. Detection of fluorescently labelled cells within the circulation was examined for all groups between 15hrs -4 days post injection (Fig. 4a, b ). Both control 3 rd party and syngeneic splenocytes were detected in the blood at similar frequencies in all groups. In naïve groups (recipients without corneal transplantation) donor (DA) splenocytes could be detected at similar frequencies to that of 3 rd party splenocytes.
However, results from recipients treated with donor derived BMDCs and Dexa BMDCs at day 65 -80 post transplantation which were injected with syngeneic and donor derived splenocyte cell mix, revealed that only the syngeneic cells were detectable 15hrs post injection (Fig. 4b ).
This indicated that donor cells were removed from the circulation at a faster rate than that of 3 rd party or syngeneic cells in both treated groups compared to that of naïve recipients, thereby showing donor responsiveness. Analysis of cell distribution within LNs, spleen and lung on day 4 post injection was performed (Fig. 4b) . It is important to note that 4 days post rechallenge of grafted animals with donor splenocytes the graft itself remained clear and did not reject ( IgG2 response of Dexa BMDC treated animals remaining similar to that of untreated transplanted animals until day 14/18 at which time a significant increase was observed (Fig.4c) .
To characterise the differences in the donor alloantibody response, we further examined the phenotype of BMDCs and Dexa BMDCs looking at the modifications in the glycome profile of Dexa BMDC cultures compared to untreated BMDCs. We found that Dexa BMDCs ( 
Discussion
It is well accepted that the immune response may be customised to the organ in which the response is initiated, as well as being specialized for the region in which it has to function 20 .
Others have demonstrated, with mixed efficacy, that the application of donor derived DCs alone/modified in combination with/without additional immunosuppressive therapies results in prolongation and tolerance of allografts, others have also reported priming of the recipient immune response 9, 10, 13, 17, 21, 22 . However, the eye is well-defined as an immune-privileged organ [23] [24] [25] and thus there may be differences in immune responses within the cornea and draining BMDCs have significantly reduced immunogenicity but also ex-vivo generated semi-mature, untreated BMDCs and in an inflammatory environment these cells express significant levels of molecules such as PD-L1 and NO.
We were interested in examining the effect of both donor derived untreated BMDC and Dexa BMDC cell administration in an in vivo transplantation model. For this, a corneal allograft transplantation model using the high-responder allogeneic strain combination of LEW recipients to DA donors was selected 9, 32 . Treatment of allograft recipients with donor derived Dexa BMDCs significantly prolonged corneal allograft survival and interestingly, significance was also observed in groups treated with unmodified donor derived BMDCs. One contributing factor for the promotion of allograft survival is the maturation status of BMDCs at the time of injection, which is a key determinant of transplantation outcomes. It is therefore important to note that allograft recipients received these BMDCs in a semi-mature phenotypic state and not in a fully (LPS-treated) matured state, as in other studies which subsequently leads to the rejection of the allograft 17 . Our results suggest that in addition to Dexa BMDCs having a strong in vivo immunomodulatory potential, untreated BMDCs also display a significant immunomodulatory capacity sufficient to promote corneal graft survival. Notably, we were unable to prolong corneal allograft survival with a systemic injection of syngeneic donor antigen pulsed Dexa BMDCs. Recently it has been suggested that it is in fact the recipient DC processing of donor DC cell therapies and immunomodulation of both in-direct and semi-direct pathways that play a significant role in the induction of allograft survival [33] [34] [35] . This may be a Despite inducing corneal allograft survival, donor BMDC and Dexa BMDC treatment was not effective at inducing peripheral donor specific unresponsiveness. Recent reports have described sensitisation of the recipient to donor antigen with pre-treatment of donor derived Dexa BMDCs 9, 13 . Our data indicating a donor specific response in the form of detectable levels of donor alloantibodies with both donor BMDC treatments supports these recent observations 9, 13 . The allo-response was however, significantly reduced with Dexa BMDC treatment, which may be due to the immunomodulatory phenotype and glycome profile of the BMDCs after Dexa treatment. Unlike the aforementioned reports which demonstrate accelerated rejection of the allografts 9,13 , in our corneal allograft model, the allografts remained protected and were not rejected. Although cell-mediated immunity is believed to play the dominant role in corneal graft rejection, the role of antibody-mediated rejection is controversial 19, 44, 45 . The immunomodulatory environment generated by treatment with donor BMDCs or donor Dexa
BMDCs may protect the corneal allograft from cell mediated immunity which in turn may promote the prevention of rejection of the cornea by complement-fixing alloantibodies.
In conclusion, we have clearly demonstrated that ex vivo generated donor Dexa BMDCs have sufficient immunomodulatory properties to significantly prolong corneal allograft survival.
Interestingly, donor derived untreated BMDCs have similar effects in this model. Although both cell therapies failed to induce peripheral donor specific unresponsiveness they did induce a local immunoregulatory milieu within the allograft and draining LNs resulting in protection of the corneal allograft. These results demonstrate a novel therapeutic application for donor derived BMDCs with and without glucocorticoid treatment for the prevention of corneal allograft rejection but also highlight the potentially contrasting results associated with DC therapies in different models of transplantation.
Materials and Methods

Animals and corneal transplantation
All procedures performed on animals were approved by the Animals Care Research Ethics 26 . Graft transparency as an indicator of rejection was evaluated every second day by light and slit lamp microscopy and graded as follows: 0 -completely transparent cornea; 0.5 -slight corneal opacity, iris structure easily visible; 1.0 -low opacity with visible iris details; 1.5 -modest corneal opacity, iris vessels still visible; 2.0 -moderate opacity, only some iris details visible; 2.5 -high corneal opacity, only pupil margin visible; 3.0 -complete corneal opacity, anterior chamber not visible. Grafts were considered rejected based on an opacity score of 2.5 for three or more consecutive days or an opacity score of 3, in combination with edema and correlating changes of transplant geometry (degree of convex contour, shrinking and surface roughness of graft) 32, 46 . Animals with surgical complications were excluded.
Generation of BMDCs
Bone marrow derived dendritic cells (BMDCs) were generated as previously described for the rat 47, 48 with some modifications. Briefly, male DA BM was flushed from both the femur and tibia; the cell suspension was collected and pelleted then re-suspended in ACK buffer to lyse the red blood cells. BM cells were washed in complete medium consisting of RPMI-1640 (Gibco, Grand Island,NY) supplemented with heat inactivated 10% FBS, 2mM L-glutamine, 0.1M non-essential amino acids, 1mM sodium pyruvate, 100U/ml penicillin, 100μg/ml streptomycin, and 55μM 2β-ME (Gibco). BM cells were then seeded in a 6 well plate at a concentration of 4.5x10 6 cells/3ml per well. The culture medium was supplemented with 5ng/ml rat GMCSF and 5ng/ml rat IL-4. Cells were then incubated at 37°C at 5% CO2. On the 
Cytokine and NO Analysis
TNF-α and IL-10 cytokine determination for BMDC supernatants, were quantified using enzyme-linked immunosorbent assay (ELISA; R&D Systems, Abingdon, UK), using the manufacturers protocols. NO release was assessed using a standard Griess Assay protocol.
Briefly, 100µl of supernatant from 1x10 6 unstimulated BMDCs/Dexa BMDCs and LPS (1µg/ml) stimulated cells in addition to the required standards (NaNO2 1 st standard 100µM in culture media) were added to the appropriate wells of a 96 flat bottom plate. 50µl of solution A (sulfanilamide, phosphoric acid, H2O) was added to each well and then 50µl of solution B
(n-(1-naphthyl)-ethylenediamine dihydrochloride, phosphoric acid, H2O). Absorbance was read at 550nm.
Allogeneic Lymphocyte Assays
Isolation of DA Ox62+ dendritic cells was carried out by MACs bead sorting as follows.
Briefly, a rat splenocyte and thymocyte cell mix (2x10 
Flow cytometry
The following monoclonal antibodies (mAbs) were used for the characterisation of BMDCs: 
Isolation of lymphocytes from transplanted corneas and lymph nodes.
Single cell suspensions from individual transplanted corneas were prepared from the excised graft. The corneal graft was excised using a 3mm trephine and vannas scissors ensuring that the graft was free of iris pigments. The graft was then stored in sterile PBS on ice. The graft was then incubated and digested with 2.5µg/ml Collagenase D (Sigma-Aldrich, Wicklow, Ireland) in a 1.5ml eppendorf and placing it into a tube shaker/heater (50 x rcf; 90 min.; 37°C).
Digestion was stopped and all liquid and tissue poured into a 100µm cell strainer and placed into a 6cm Petri dish. The cornea graft was further disintegrated by mashing with the head of a syringe plunger. The cell suspension was collected in a 15ml falcon tube and the cell strainer and Petri dish thoroughly rinsed and added to cell suspension. The sample was centrifuged (400 x rcf; 3min.; 4°C) and resuspended in 1.2mls of FACS buffer for counting. Ipsilateral submandibular and cervical LNs were also homogenised with the syringe plunger and passed through a 100 µM cell strainer. Cell suspensions were transferred into 15 ml tubes, spun at 400
x rcf for 5 min and washed again with PBS. Cell suspensions from individual corneas and LNs were resuspended in FACS buffer and used for subsequent flow cytometry. 
RNA-Isolation and RT-PCR
Histology and histochemistry
For histological analysis rat eyes were enucleated at day 18 after transplantation for all groups and at the end of the observation period for graft survival on day 30. Briefly, the eyes embedded in paraffin wax were cut for 5 µm thick sections, dried overnight at 56°C and then deparaffinized twice in xylene for 10 min, followed by hydration through graded alcohols.
Slides were incubated for 40 s in Harris hematoxylin, washed in tap water for 2 min, then stained in eosin for 7 min, washed again in water for 2 min and dehydrated through graded alcohols. Next, sections were cleared twice for 10 min in xylene and mounted in DPX (Sigma-Aldrich, Wicklow, Ireland).
In vivo Cell Trace Experiment
Spleens and thymi were harvested from LEW (syngeneic) GFP transgenic, DA (donor) and CD (3 rd party) rats, organs were homogenised and treated with ACK as previously described. Cells from donor and 3 rd party origins were stained using CellTrace Far Red DDAO-SE (as per 
Harvest of Autologous Serum and Detection of allo-antibodies
Blood from untreated controls, treated groups and naïve controls, was withdrawn from tail vein using a 25G needle and transferred into a sterile 1.5ml eppendorf tube containing 100µl PBS and heparin (2U/ml). The blood was then centrifuged (500 x rcf; 10 min.; 4°C) and the resulting serum fraction was harvested with a sterile pipette and transferred into 1.5ml micro reaction tubes. The serum was stored at -20°C for later use. Alloantibody analysis was performed as reported previously 49 . Recipient serum was diluted (1:2 in FACS buffer) and incubated with 1×10 6 DA splenocytes for 45 minutes on ice in a total volume of 50µl per test. Samples were washed twice with FACS buffer and pelleted (400×rcf for 5 min. at 4°C). In the fashion of a secondary FACS stain, samples were then labelled with either anti-rat IgM-PE, IgG1-FITC or IgG2a-FITC (all from Antibodies-online, Germany). In the case of anti-IgM-PE staining, anti-CD45RA-FITC (BD Biosciences) was added to later allow exclusion of B cells from analysis.
Splenocytes were incubated further for 45 min on ice, washed and resuspended in FACS buffer for analysis using a FACS Canto.
Statistics
Statistical analysis was performed by GraphPad Prism software (La Jolla, USA) using nonparametric Mann-Whitney or two-tailed parametric Student T-test where appropriate, unless otherwise stated in text. Survival data were compared using the Mantel-Cox log rank test.
Differences were considered significant if p ≤ 0.05. 
